In addition to less improvement in insulin resistance, patients with baseline BG120 below 8.1 mmol/l had a greater reduction in insulin secretion, which indicated that there was more chance of deteriorating glucose tolerance status after SSA treatment in these subjects. The gene discussed is INS; the disease is Insulin resistance.